The retirement of David Cordani as CEO of The Cigna Group will be the fourth departure of a long-time health insurance executive during a turbulent time for the industry.
It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.
Centenarians share a distinct, youth‑like blood protein profile in immune, metabolic, and repair pathways, suggesting circulating factors may help sustain exceptional longevity.
This is less than a year after the Teal Wand from Teal Health became the first at-home cervical cancer screening test approved by the U.S. Food and Drug Administration.
For asymptomatic people without known risks, the downsides and uncertainties of multi-cancer early detection testing could outweigh potential benefits.
The Cigna Group’s long-time CEO David M. Cordani will retire effective July 1 and be replaced by current president and chief operating officer Brian Evanko.
MMI is starting FDA-approved human trials for its tiny robot to use needles the size of eyelashes to help clear waste from the brains of Alzheimer’s patients.
New study finds that the costs of removing motorcycle helmet laws continue to rise for both hospitals and taxpayers.
A public health expert examines how ‘The Pitt’ portrays obesity with clinical dignity—and what real-world medicine often misses about weight bias and patient safety.
Ascendiun CEO Paul Markovich launches new lobbying in an effort to force the health industry to become more accessible and affordable.